Latest news

Needham analyst Mike Matson maintains Conmed (NYSE:CNMD) with a Buy and lowers the price target from $127 to $123.

Conmed (NYSE:CNMD) reported its Q2 earnings results on Wednesday, July 27, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Conmed beat estimated earnings by 1.33%, reporting an EPS of $0.76 versus an estimate of $0.75.

  Companies Reporting Before The Bell • Equinor (NYSE:EQNR) is projected to report earnings for its second quarter.

  On Wednesday, 329 companies hit new 52-week lows.

  On Friday, 422 stocks made new 52-week lows.

  On Thursday, 126 companies set new 52-week lows.

Gainers

  On Friday, 1043 companies hit new 52-week lows.

Needham analyst Mike Matson maintains Conmed (NYSE:CNMD) with a Buy and raises the price target from $150 to $155.

  Companies Reporting Before The Bell • Seres Therapeutics (NASDAQ:MCRB) is estimated to report quarterly loss at $0.52 per share on revenue of $8.48 million.